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We recently described that IRF-1 is important for IFNc mediated immune surveillance in metastasis. Despite the
upregulation of MHC Class I in tumor cells, IRF-1 leads to a NK cell-dependent elimination of tumor cells. This mechanism
is independent on inhibitory receptors and cytotoxic granules but dependent on DNAM-1.
The theory of cancer immunoediting
suggests three distinct phases of tumor
development: elimination, equilibrium
and escape.
1 During the elimination phase,
transformed cells are recognized and
eliminated by cells of the innate and
adaptive immunity. If the antitumor
immunity is unable to completely elimi-
nate transformed cells, tumor variants can
survive and enter an equilibrium phase,
where cells and molecules of the immune
system can prevent tumor outgrowth.
Due to possible mutations, new highly
immunogenic tumor variants can emerge
which escape the immune system and
favor progression to detectable malignan-
cies. T-, NKT- and especially NK-cells as
well as Type I and Type II IFNs play a
central role in the process of cancer
immunoediting.
2
IFNc plays a pivotal role in antitumor
responses since mice deficient in IFNc or
the IFNc receptor show increased tumor
development. IFNc promotes direct
tumor suppressive effects by inhibiting
cellular proliferation, promoting apoptosis
and inhibiting angiogenesis.
The transcription factor IRF-1 is critical
for IFNc-mediated effects. IRF-1 is con-
stitutively expressed at low levels in most
cell types and its transcription is induced
by IFNc, proinflammatory cytokines,
dsRNA and genotoxic stress. IRF-1 exerts
a variety of biological processes including
inflammation, antiviral response, immune
regulation and tumor suppression.
3 Ecto-
pic expression of IRF-1 inhibits prolifera-
tion and reverses e phenotype of cells
transformed by various oncogenes. Dele-
tion in the IRF-1 gene has been implicated
in cancers thereby indicating its role as a
tumor suppressor gene. Furthermore, the
role of IRF-1 in immune responses was
demonstrated by the induction of anti-




4 Tumor suppressive func-
tions of IRF-1 are exhibited by the induc-
tion of target genes involved in cell cycle
control or apoptotic processes. Interestingly,
deletion of IRF-1 alone does not promote
tumorigenesis but enhances the extent of
tumors arising from p53 deletions.
IFNc has been proposed to control
tumor development. In Ksienzyk et al.,
5
on the hypothesis of stimulation of IRF-1
upon IFNc treatment we addressed
whether IRF-1 had any role in disease
progression and the mechanism of
metastasis development. To this end,
we administered IFNc to mice with
experimental pulmonary lung metastases.
Intranasal application inhibited the
development of metastases. We identified
IRF-1 as a major mediator of this effect
because blockage by short hairpin RNAs
abolished the inhibitory effect of IFNc on
tumor metastasis. To address the mecha-
nism of this inhibitory phenotype, we
used slight ectopic expression of IRF-1
which phenocopied the inhibitory effect
of IFNc. To define the level at which
inhibition takes place we induced IRF-1
expression at different stages of metastasis
development and showed that IRF-1
reduces development of metastatic nodules
in the lungs rather than influencing the
survival of circulating cells or their entry in
the lungs.
When we studied the potential mecha-
nisms underlying this phenotype, we
found that IRF-1 mediates its influence
on the tumor microenvironment. By the
production of the chemokine CXCL11
especially CXCR3 positive NK cells infilt-
rate in the lungs. Studies with mutant
mice strains and depleting antibodies
revealed that NK cells are responsible for
the IRF-1 mediated inhibition of lung
metastasis. NK cells are important media-
tors of antitumor immunity and mice with
decreased levels of NK cells have increased
susceptibility to metastasis and tumor
growth.
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NK cells recognize and eliminate cells
through a complex set of activating and
inhibiting receptors.
6 Loss of MHC class I
molecules leads to NK cell mediated
elimination of tumor cells. However, we
showed that IRF-1 expression in tumor
cells induce MHC class I molecules on the
surface of tumor cells. Thus, IRF-1 tips
the balance between activating and inhibi-
tory signals toward activation by other
mechanisms. Other studies have indicated
NK cell activation by NKG2D ligands and
other activating receptors like DNAX-
accessory molecule-1 (DNAM-1) in the
presence of MHC class I expression.
7,8
Recently it was reported that DNAM-1
together with other activating receptors
induce NK cell mediated killing.
9 By using
DNAM-1
2/2 mice and TRAIL depleting
antibodies we showed that IRF-1 attracts
NK cells to the metastatic lungs which kill
the tumor cells by DNAM-1 dependent
mechanisms.
We showed that IRF-1 is a key
mediator of IFN-c mediated immune
surveillance, influencing the tumor micro-
environment and resulting in the attrac-
tion of immune cells which are able to
recognize and eliminate tumor cells. IRF-1
is induced by proinflammatory reaction.
We have shown that even low expression
of IRF-1 is sufficient to inhibit metastasis
and prolonged survival. Induction of
IRF-1 in the tumor microenvironment
by proinflammatory cytokines or small
molecules could direct the immune system
toward efficacious anti tumor response and
could be an attractive target for cancer
therapy.
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Figure1. Schematic representation of IRF-1 mediated inhibition of metastasis. (A) Tumor cells
expressing IRF-1 influence the tumor mircroenvironment by induction of CXCL11. CXCR3
+ NK cells
infiltrate to the site of tumor development and eliminate the tumor cells. (B) Expression of IRF-1
influence both, tumor cells and attracted NK cells. Tumor cells upregulate DR5 and CD155 whereas
activated NK cells express DNAM-1 and TRAIL which leads to NK cell mediated tumor cell
elimination.
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